Alternative and complementary therapies for the menopause

Menopause International

Volumn 18, Issue 1, 2012, Pages 20-27

  Pitkin, Joan ^a  

^a ST MARK S HOSPITAL   (United Kingdom)

Author keywords

breast cancer; depression; isoflavones; red clover; Soy

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CIMICIFUGA RACEMOSA EXTRACT; CITALOPRAM; CLONIDINE; ESTRADIOL; FLUOXETINE; GABAPENTIN; ISOFLAVONE; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; PHENELZINE; PHYTOESTROGEN; PRASTERONE; PROGESTERONE; PROPRANOLOL; RED CLOVER EXTRACT; SEROTONIN UPTAKE INHIBITOR; TAMOXIFEN; VENLAFAXINE; WARFARIN;

ALTERNATIVE MEDICINE; ANGELICA SINENSIS; BREAST CANCER; CANCER CELL CULTURE; DEPRESSION; GINKGO BILOBA; GINSENG; HUMAN; HYPERICUM PERFORATUM; MENOPAUSE; MOOD; REVIEW; SOYBEAN; VITEX AGNUS CASTUS;

COMPLEMENTARY THERAPIES; FEMALE; HOT FLASHES; HUMANS; MENOPAUSE; PHYTOESTROGENS; PHYTOTHERAPY; PLANT PREPARATIONS;

EID: 84858199653     PISSN: 17540453     EISSN: 17540461     Source Type: Journal    
DOI: 10.1258/mi.2012.012001     Document Type: Review

References (68)

1. Cumming G, Currie H, Beck S, Moncur R. Provision of menopause information: do we get it right? A web-based survey on provision of menopause treatment information by health-care professionals to a computer-literate population accessing a menopause website. Menopause International 2011; 17: 112–13
2. Wren BG, Brown LB. A double blind trial with clonidine and a placebo to treat hot flushes. Med J Aus 1986; 144: 369–70
3. Goldberg RM, Loprinzi CL, O’Fallon JR,, et al. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol 1994; 12: 155–158
4. Nelson H, Vesco K, Haney E,, et al. Non-hormonal therapies for menopausal hot flushes: systematic review and meta-analysis. JAMA 2006; 295: 2057–71
5. Burbos N, Morris EP. Menopausal symptoms. Clin Evid (Online) 2011; Jun 15
6. Jin Y, Desta Z, Stearns V,, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005; 97: 30–39
7. Tanna N, Woyka J, Abernethy K, Reichert R, Pitkin J. A joint specialist breast cancer and menopause symptoms (BCMS) clinic: service development using a clinical governance approach. Eur J Surg Oncol 2009; 35: 1242
8. Guttuso T Jr, Kurlan R, McDermott MP, Kieburz K. Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2003; 101: 337–45
9. Aguirre W, Chedraui P, Mendoza J, Ruilova I. Gabapentin vs. low-dose transdermal estradiol for treating post-menopausal women with moderate to very severe hot flushes. Gynecol Endocrinol 2010; 26: 333–337
10. Panjari M, Davis SR. DHEA for postmenopausal women: a review of the evidence. Maturitas 2010; 66: 172–179
11. Barton DL, Loprinzi C, Atherton PJ,, et al. Dehydroepi-androsterone for the treatment of hot flashes: a pilot study. Support Cancer Ther 2006; 3: 91–97
12. Loprinzi CL, Michalak JC, Quella SK,, et al. Megestrol acetate for the prevention of hot flashes. N Engl J Med 1994; 331: 347–52
13. Vasilakis C, Jick H, del Mar Melero-Montes M. Risk of idiopathic venous thromboembolism in users of progestogens alone. Lancet 1999; 354: 1610–1
14. Leonetti HB, Longo S, Anasti JN. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obstet Gynecol 1999; 94: 225–228
15. Wren BG, Champion SM, Willetts K, Manga RZ, Eden JA. Transdermal progesterone and its effect on vasomotor symptoms, blood lipid levels, bone metabolic markers, moods, and quality of life for postmenopausal women. Menopause 2003; 10: 13–18
16. Lee MS, Shin BC, Ernst E. Acupuncture for treating menopausal hot flushes: a systematic review. Climacteric 2009; 12: 16–25
17. Medicines and Healthcare Regulatory Agency. Drug Safety Update Dec 2007; Vol 1 Issue 5: 15
18. Clarke DB, Bailey V, Lloyd AS. Determination of phytoestrogens in dietary supplements by LC-MS/MS. Food Addit Contam Part A Chem Anal Control Expo Risk Assess 2008; 25: 534–47
19. Linde K, Ramirez G, Mulrow CD,, et al. St John's wort for depression – an overview and meta-analysis of randomised clinical trials. BMJ 1996; 313: 253–258
20. Wuttke W, Seidlova-Wuttke D, Gorkow C. The Cimicifuga preparation BNO 1055 vs. conjugated estrogens in a double-blind placebo-controlled study: effects on menopause symptoms and bone markers. Maturitas 2003; 44: 67–77
21. Frei-Kleiner S, Schaffner W, Rahlfs VW, Bodmer C, Birkhäuser M. Cimicifuga racemosa dried ethanolic extract in menopausal disorders: a double-blind placebo-controlled clinical trial. Maturitas 2005; 51: 397–404
22. Jacobson JS, Troxel AB, Evans J,, et al. Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol 2001; 19: 2739–45
23. Committee on Safety of Mecicines and the Medicines and Healthcare Regulatory Agency. Black Cohosh (cimicifuga racemosa) and hepatotoxicity. Current Problems in Pharmacovigilance 2004; 30:10
24. Huntley A, Ernst E. A systematic review of the safety of black cohosh. Menopause 2003; 10: 58–64
25. Wiklund IK, Mattsson LA, Lindgren R,, et al. Effects of a standardized ginseng extract on quality of life and physiological parameters in symptomatic postmenopausal women: a double-blind, placebo-controlled trial. Int J Clin Pharmacol Res 1999; 19: 89–99
26. Hirata JD, Swiersz LM, Zell B,, et al. Does dong quai have estrogenic effects in postmenopausal women? A double-blind, placebo-controlled trial. Fertil Steril 1997; 68: 981–986
27. Elsabagh S, Hartley S, File S. Limited cognitive benefits in Stage +2 postmenopausal women after 6 weeks of treatment with Ginkgo biloba. J Psychopharmacol 2005; 19: 173–81
28. Dornstauder E, Jisa E, Unterrieder I,, et al. Estrogenic activity of two standardized red clover extracts (Menoflavon) intended for large scale use in hormone replacement therapy. J Steroid Biochem Mol Biol 2001; 78: 67–75. PubMed PMID: 11530286
29. Tham DM, Gardner CD, Haskell WL. Potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence. J Clin Endocrinol Metab 1998; 83: 2223–35
30. Chiechi LM, Micheli L. Utility of dietary phytoestrogens in preventing postmenopausal osteoporosis. Curr Topics Nutraceut Res 2005; 3: 15–28
31. Setchell KDR, Brown NM, Desai P,, et al. Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J Nutr 2001; 131: 1362S–1375S
32. Koebnick C, Reimann M, Carlsohn A,, et al. The acceptability of isoflavones as a treatment of menopausal symptoms: a European survey among postmenopausal women. Climacteric 2005; 8: 230–42. PubMed PMID: 16390755
33. Lethaby AE, Brown J, Marjoribanks J, Kronenberg F, Roberts H, Eden J. Phytoestrogens for vasomotor menopausal symptoms. Cochrane Database Syst Rev 2007;(4):CD001395
34. Balk E, Chung M, Chew P,, et al. Effects of soy on health outcomes. Evid Rep Technol Assess (Summ) 2005; 126: 1–8
35. Huntley AL, Ernst E. Soy for the treatment of perimenopausal symptoms – a systematic review. Maturitas 2004; 47: 1–9
36. Imhof M, Molzer S, Imhof M. Effects of soy isoflavones on 17beta-estradiol-induced proliferation of MCF-7 breast cancer cells. Toxicol In Vitro 2008; 22: 1452–60. Epub 4 May2008. PubMed PMID: 18554862
37. Unfer V, Casini ML, Castabile L,, et al. Endometrial effects of long-term treatment with phyto-estrogens: a randomized, double-blind, placebo-controlled study. Fertil Steril 2004; 82: 145–148
38. Howes LG, Howes JB, Knight DC. Isoflavone therapy for menopausal flushes: a systematic review and meta-analysis. Maturitas 2006; 55: 203–11
39. Van de Weijer PHM, Barentsen R. Isoflavones from red clover (Promensil*) significantly reduce menopausal hot flush symptoms compared to placebo. Maturitas 2002; 42: 187–93
40. Jeri AR. The use of an isoflavone supplement to relieve hot flushes. Female Patient 2002; 27: 35–37
41. Nachtigall LB, Nachtigall MJ, Nachtigall LE. Nonprescription alternatives to hormone replacement therapy. Female Patient 1999; 24: 45–50
42. Nachtigall LE, Baber RJ, Barentsen R,, et al. Complementary and hormonal therapy for vasomotor symptom relief: a conservative clinical approach. J Obstet Gynaecol Can 2006; 28: 279–89
43. Lipovac M, Chedraui P, Gruenhut C,, et al. The effect of red clover isoflavone supplementation over vasomotor and menopausal symptoms in postmenopausal women. Gynecol Endocrinol 2011; Aug 26 [Epub ahead of print]
44. Atkinson C, Warren R, Sala E. Red clover-derived isoflavones and mammographic breast density: a double-blind, randomized, placebo-controlled trial [ISRCTN42940165] Breast Cancer Res 2004; 6: R170–R179
45. Powles TJ, Howell A, Evans DG,, et al. Red clover isoflavones are safe and well tolerated in women with a family history of breast cancer. Menopause Int 2008; 14: 6–12. PubMed PMID: 18380954
46. Hale GE, Hughes CL, Robboy SJ,, et al. A double-blind randomized study on the effects of red clover isoflavones on the endometrium. Menopause 2001; 8: 338–46
47. Baber R, Bligh PC, Fulcher G,, et al. The effect of an Isoflavone dietary supplement (P-081) on serum lipids, forearm bone density & endometrial thickness in post menopausal women [abstract]. Menopause 1999a; 6: 326
48. Woods R, Colville N, Blazquez J,, et al. Effects of red clover isoflavones (Promensil*) versus placebo on uterine endometrium, vaginal maturation index and the uterine artery in healthy postmenopausal women. J Br Menopause Soc 2004; 10(Supplement 2):17
49. Clifton-Bligh PB, Baber RJ, Fulcher GR, Nery ML, Moreton T. The effect of isoflavones extracted from red clover (Rimostil) on lipid and bone metabolism. Menopause 2001; 8: 259–65
50. Imhof M, Gocan A, Reithmayr F,, et al. Effects of a red clover extract (MF11RCE) on endometrium and sex hormones in postmenopausal women. Maturitas 2006; 55: 76–81. Epub 2006 Mar 2. PubMed PMID: 16513301
51. Fugh-Berman A, Kronenberg F. Red clover (Trifolium pratense) for menopausal women: current state of knowledge. Menopause 2001; 8: 333–7. Review. PubMed PMID: 11528359
52. Hidalgo LA, Chedraui PA, Morocho N,, et al. The effect of red clover isoflavones on menopausal symptoms, lipids and vaginal cytology in menopausal women: A randomized, double-blind, placebo-controlled study. Gynecol Endocrinol 2005; 21: 257–64
53. Jeri A, Rossi P. Effects of isoflavones phytoestrogens on lipid profile on postmenopausal peruvian women. Book of Abstracts 10th World Congress on the Menopause. Climacteric 2002; 5(Sup. Abstract F):27–106
54. Nestel PJ, Pomeroy S, Kay S,, et al. Isoflavones from red clover improve systemic arterial compliance but not plasma lipids in menopausal women. J Clin Endocrinol Metab 1999; 84: 895–898
55. Ingram D, Sanders K, Kolybaba M,, et al. Case-control study of phyto-oestrogens and breast cancer. Lancet 1997; 350: 990–994
56. Bodo C, Rissman EF. New roles for estrogen receptor beta in behavior and neuroendocrinology. Front Neuroendocrinol 2006; 27: 217–32. Epub 2006 Apr 17. Review. PubMed PMID: 16603234
57. Craig MC, Murphy DG. Estrogen: effects on normal brain function and neuropsychiatric disorders. Climacteric 2007; 10(Supplement 2):97–104
58. Albert A, Altabre C, Baró F,, et al. Efficacy and safety of a phytoestrogen preparation derived from Glycine max (L.) Merr in climacteric symptomatology: a multicentric, open, prospective and non-randomized trial. Phytomedicine 2002; 9: 85–92. PubMed PMID: 11995954
59. Lipovac M, Chedraui P, Gruenhut C,, et al. Improvement of postmenopausal depressive and anxiety symptoms after treatment with isoflavones derived from red clover extracts. Maturitas 2010; 65: 58–61. Epub 2009 Nov 30. PubMed PMID: 19948385
60. Shu XO, Jin F, Dai Q,, et al. Soyfood intake during adolescence and subsequent risk of breast cancer among Chinese women. Cancer Epidemiol Biomarkers Prev 2001; 10: 483–8. PubMed PMID: 11352858
61. Key T, Fraser GE, Thorogood M,, et al. Mortality in vegetarians and nonvegetarians: detailed findings from a collaborative analysis of 5 prospective studies. Am J Clin Nutr 1999; 70: 516S–524S
62. Maskarinec G. Breast cancer – interaction between ethnicity and environment. In Vivo 2000; 14: 115–23. Review. PubMed PMID: 10757068
63. Messina M, Persky V, Setchell KDR, Barnes S. Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer 1994; 21: 113–31
64. Adlercreutz H, Mazur W. Phyto-oestrogens and Western diseases. Ann Med 1997; 29: 95–120. Review. PubMed PMID: 9187225
65. Messina MJ, Loprinzi CL. Soy for breast cancer survivors: a critical review of the literature. J Nutr 2001; 131(11 Supplement):3095S–3108S. Review. PubMed PMID:11694655
66. Shu XO, Zheng Y, Cai H,, et al. Soy food intake and breast cancer survival. JAMA 2009; 302: 2437–43. PubMed PMID: 19996398; PubMed Central PMCID: MC2874068
67. Pitkin J, Rees M, Gray S, BMS (2007) Alternative and complementary therapies. British Menopause Society Council Consensus Statement. See www.thebms.org.uk (last accessed 7 February 2012)
68. Sturdee DW, Collins P, Genazzani AR, Simoncini T, eds. Aging, menopause, cardiovascular disease and HRT 8th International Menopause Society Workshop February 2009 Consensus Statement. Climacteric 2009; 12: 368–77